Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-03-21

FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XTANDI (enzalutamide) from Astellas Pharma US, Inc. The action updates the product's approved use or labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xtandi (enzalutamide)

Snippet

SUPPL AP for XTANDI (ENZALUTAMIDE)